Osmotica Pharmaceuticals plc·4

May 20, 9:48 PM ET

Einhorn Andrew J. 4

4 · Osmotica Pharmaceuticals plc · Filed May 20, 2020

Insider Transaction Report

Form 4
Period: 2020-05-18
Einhorn Andrew J.
Chief Financial Officer
Transactions
  • Award

    Ordinary Shares

    2020-05-18+71,550167,215 total
  • Award

    Performance-Based Restricted Stock Units

    2020-05-18+71,55071,550 total
    Ordinary Shares (71,550 underlying)
Holdings
  • Ordinary Shares

    (indirect: By family limited liability company)
    22,852
Footnotes (3)
  • [F1]Represents a grant of restricted stock units.
  • [F2]The Reporting Person is the sole managing member of the limited liability company and, as a result, may be deemed to beneficially own the ordinary shares held by the limited liability company. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
  • [F3]The performance-based restricted stock units represent a contingent right to receive, upon vesting, a varying number of the registrant's ordinary shares based on certain pre-determined thresholds for the closing price of registrant's ordinary shares on the Nasdaq Global Select Market. The performance-based restricted stock units vest on the third anniversary of the date of grant and, upon vesting, will convert into 0%, 50%, 100% or 150% of the target number of ordinary shares listed in Column 7 of Table II.

Documents

1 file
  • 4
    a4.xmlPrimary

    4